Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 3269

Similar articles for PubMed (Select 18252677)

1.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
2.

Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.

Ross AE, D'Amico AV, Freedland SJ.

Prostate Cancer Prostatic Dis. 2015 Jun 30. doi: 10.1038/pcan.2015.31. [Epub ahead of print] Review.

PMID:
26123120
3.

External beam radiotherapy for localized prostate cancer.

Yilmaz H, Aksu G, Dillioglugil O.

Asian J Androl. 2015 Jun 26. doi: 10.4103/1008-682X.156857. [Epub ahead of print]

4.

Primary radiotherapy vs conservative management for localized prostate cancer-a population-based study.

Lu-Yao GL, Kim S, Moore DF, Shih W, Lin Y, DiPaola RS, Shen S, Zietman A, Yao SL.

Prostate Cancer Prostatic Dis. 2015 Jun 23. doi: 10.1038/pcan.2015.30. [Epub ahead of print]

PMID:
26101187
5.

Factors influencing inclusion in digestive cancer clinical trials: A population-based study.

Frérot M, Jooste V, Binquet C, Fournel I, Bedenne L, Bouvier AM.

Dig Liver Dis. 2015 May 28. pii: S1590-8658(15)00346-1. doi: 10.1016/j.dld.2015.05.017. [Epub ahead of print]

PMID:
26089036
6.

Urologic cancer in Indonesia.

Umbas R, Safriadi F, Mochtar CA, Djatisoesanto W, Hamid AR.

Jpn J Clin Oncol. 2015 Jun 16. pii: hyv066. [Epub ahead of print] Review.

PMID:
26085688
7.

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial.

Denham JW, Steigler A, Joseph D, Lamb DS, Spry NA, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai KH, Gogna NK, Gill S, Tan H, Kearvell R, Murray J, Ebert M, Haworth A, Kennedy A, Delahunt B, Oldmeadow C, Holliday EG, Attia J.

Radiother Oncol. 2015 Jun 10. pii: S0167-8140(15)00269-8. doi: 10.1016/j.radonc.2015.05.016. [Epub ahead of print]

PMID:
26072289
8.

Does Androgen Deprivation Therapy for Prostate Cancer Increase the Risk of Colorectal Cancer?

Martling A.

Cancer Control. 2015 Apr;22(2):261-2. No abstract available.

9.

Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis.

Qiao L, Liang Y, Li N, Hu X, Luo D, Gu J, Lu Y, Zheng Q.

Int J Clin Exp Med. 2015 Mar 15;8(3):3465-73. eCollection 2015.

10.

Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status.

Faria EF, Chapin BF, Muller RL, Machado RD, Reis RB, Matin SF.

Urology. 2015 Jun 2. pii: S0090-4295(15)00265-4. doi: 10.1016/j.urology.2015.03.012. [Epub ahead of print] Review.

PMID:
26048432
11.

A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation.

Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, Beyer B, Moschini M, Gratzke C, Steuber T, Suardi N, Briganti A, Manka L, Nyberg T, Dutton SJ, Wiklund P, Graefen M.

Eur Urol. 2015 May 30. pii: S0302-2838(15)00425-X. doi: 10.1016/j.eururo.2015.05.023. [Epub ahead of print]

PMID:
26038098
12.

An early-detection programme for prostate cancer in Saudi men: A call from a tertiary-care centre in the Eastern province.

Osman E, Gomha MA, Harb A, Aldayel A, Aloraifi I, Almousa R, Khan I.

Arab J Urol. 2014 Sep;12(3):187-91. doi: 10.1016/j.aju.2014.04.003. Epub 2014 May 13.

13.

Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives.

Bayne CE, Williams SB, Cooperberg MR, Gleave ME, Graefen M, Montorsi F, Novara G, Smaldone MC, Sooriakumaran P, Wiklund PN, Chapin BF.

Eur Urol. 2015 May 20. pii: S0302-2838(15)00378-4. doi: 10.1016/j.eururo.2015.04.036. [Epub ahead of print] Review.

PMID:
26003223
14.

Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives.

Kitagawa Y, Ueno S, Konaka H, Mizokami A, Hinotsu S, Akaza H, Namiki M.

Curr Cancer Drug Targets. 2015;15(4):314-26.

PMID:
26003144
15.

Comparative effectiveness research in cancer with observational data.

Giordano SH.

Am Soc Clin Oncol Educ Book. 2015;35:e330-5. doi: 10.14694/EdBook_AM.2015.35.e330.

16.

Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.

Muralidhar V, Dinh KT, Mahal BA, Ziehr DR, Chen YW, Viswanathan VB, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL.

Urol Oncol. 2015 Jul;33(7):330.e19-25. doi: 10.1016/j.urolonc.2015.03.010. Epub 2015 May 16.

PMID:
25990612
17.

Re: low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer.

Seftel AD.

J Urol. 2015 Jun;193(6):1985-6. doi: 10.1016/j.juro.2015.03.066. Epub 2015 Mar 14. No abstract available.

PMID:
25986798
18.
19.

Re: patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer.

Taneja SS.

J Urol. 2015 Jun;193(6):1982-3. doi: 10.1016/j.juro.2015.03.045. Epub 2015 Mar 14. No abstract available.

PMID:
25986793
20.

The effect of age on functional outcomes after radical prostatectomy.

Bolat D, Gunlusoy B.

Urol Oncol. 2015 Jul;33(7):333. doi: 10.1016/j.urolonc.2015.04.009. Epub 2015 May 16. No abstract available.

PMID:
25985713
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk